Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

The medications still amount to around $500 per month for those without insurance — out of reach for many patients. Even for people with insurance, coverage remains uneven.

“The medications should be available, the question is at what price and can people sustain that,” said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage.

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity.

Zepbound brought in $2.3 billion in U.S. sales during this year’s first quarter, making it one of drugmaker Eli Lilly’s best sellers.

Novo Nordisk says Wegovy has about 200,000 weekly prescriptions in the United States, where it brought in nearly $1.9 billion in first-quarter sales.

The benefits consultant Mercer says more businesses with 500 or more employees are adding coverage of the injected drugs for their workers and family members.

Novo says 85 percent of its patients who have coverage in the United States pay $25 or less per month.

Plus some patients with diabetes can get coverage of the GLP-1 drugs Ozempic and Mounjaro from Novo and Lilly that are approved to treat that condition.

Most state and federally funded Medicaid programs don’t cover the drugs for obesity and neither does Medicare, the federal program mainly for people age 65 and older.

Even the plans that cover the drugs often pay only a portion of the bill, exposing patients to hundreds of dollars in monthly costs, said Dr. Beverly Tchang.

Drugmakers offer help with these out-of-pocket costs, but that assistance can be limited.

“Coverage is not the same as access,” said Tchang, a New York-based doctor who serves as a paid adviser to both Novo and Lilly.

Bill-payers such as employers are nervous about drugs that might be used by a lot of people indefinitely.

Some big employers have dropped coverage of the drugs due to the expense. Pharmacy benefit managers, or PBMs, also are starting to pick one brand over the other as they negotiate deals with the drugmakers.

One of the nation’s largest PBMs, run by CVS Health, dropped Zepbound from its national formulary, or list of covered drugs, on July 1 in favor of Wegovy.

That forced Tchang to figure out another treatment plan for several patients, many of whom took Zepbound because it made them less nauseous.